AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease
- Conditions
- Hyperlipidemia
- First Posted Date
- 2006-02-27
- Last Posted Date
- 2011-06-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 237
- Registration Number
- NCT00296400
- Locations
- 🇿🇦
Research Site, Pretoria, South Africa
Effects in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome
- Conditions
- Acute Coronary Syndrome
- First Posted Date
- 2006-02-27
- Last Posted Date
- 2007-12-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1160
- Registration Number
- NCT00296387
- Locations
- 🇪🇸
Research site, Madrid, Spain
🇹🇳Research Site, Tunis, Tunisia
Secondary Adjuvant Long Term Study With Arimidex
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3484
- Registration Number
- NCT00295620
- Locations
- 🇦🇹
Research Site, Zams, Austria
A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 565
- Registration Number
- NCT00295633
- Locations
- 🇺🇸
Sunbelt Research Group, Llc, Mobile, Alabama, United States
🇺🇸Loma Linda Va Healthcare Systems, Loma Linda, California, United States
🇺🇸Mouhaffel, Assad H., West Monroe, Louisiana, United States
ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.
- Conditions
- Breast Cancer
- First Posted Date
- 2006-02-15
- Last Posted Date
- 2013-01-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3858
- Registration Number
- NCT00291759
- Locations
- 🇦🇹
Research Site, Zams, Austria
🇦🇹Research Sites, Vienna, Austria
🇦🇹Research SIte, Melk, Austria
Validation of RDQ Questionnaire
- Conditions
- Gastroesophageal Reflux
- First Posted Date
- 2006-02-15
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 350
- Registration Number
- NCT00291746
- Locations
- 🇬🇧
Research Site, West Bromwich, United Kingdom
SALTO - Symbicort Single Inhaler Therapy Use in Adolescent Adults and Adults With Persistent Asthma
- Conditions
- Asthma
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT00290264
- Locations
- 🇱🇺
Research Site, Warken, Luxembourg
🇱🇺Research site, Luxembourg, Luxembourg
SMILDA - Symbicort®Turbuhaler® Allergan Challenge Study in Allergic Patients With Mild Asthma
- Conditions
- Asthma
- First Posted Date
- 2006-02-08
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT00288379
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2009-06-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1059
- Registration Number
- NCT00287534
- Locations
- 🇩🇪
Research Site, Wuerzburg, Germany
ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years
- First Posted Date
- 2006-02-03
- Last Posted Date
- 2009-05-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 448
- Registration Number
- NCT00286117
- Locations
- 🇮🇹
Research Site, Vicenza, Italy